Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies
Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed suc...
Gespeichert in:
| Veröffentlicht in: | Antiviral research 2016-09, Vol.133, p.218-222 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 222 |
|---|---|
| container_issue | |
| container_start_page | 218 |
| container_title | Antiviral research |
| container_volume | 133 |
| creator | Cross, Robert W. Mire, Chad E. Branco, Luis M. Geisbert, Joan B. Rowland, Megan M. Heinrich, Megan L. Goba, Augustine Momoh, Mambu Grant, Donald S. Fullah, Mohamed Khan, Sheik Humarr Robinson, James E. Geisbert, Thomas W. Garry, Robert F. |
| description | Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
•125 Lassa glycoprotein-specific huMAbs were assessed for in vitro activity.•Eleven huMAbs were assessed in an outbred guinea pig model of Lassa fever.•Five huMAbs completely protected animals when given shortly after Lassa exposure. |
| doi_str_mv | 10.1016/j.antiviral.2016.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5032844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354216303515</els_id><sourcerecordid>1821097852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-73e23871c6f5e14cf21f6c65e845b6aedc462979181ea5266a574daab6a354373</originalsourceid><addsrcrecordid>eNqNUcuOEzEQtBCIDQu_AD5ymcGP8WMuSKsV7CJF4rKcLcfTkziasYPtCeJv-Ba-DEdZIjjByS1XdXVXF0JvKGkpofLdvrWh-KNPdmpZ_WiJbgllT9CKasWanvTyKVpVQDZcdOwKvch5TwiRqtfP0RVTglMu1QrtHxLYMkMoOI54bXO2uMouGfswgis-hlrhuJRNggFvFx_A4oPfZvzNlx0efcql8aFxU-39-WO3zDbgOYbophjshE97buLgIb9Ez0Y7ZXj1-F6jLx8_PNzeN-vPd59ub9aNE0SXRnFgXCvq5CiAdm5kdJROCtCd2EgLg-sk61VPNQUrmJRWqG6wtmLVKlf8Gr0_6x6WzVzp1Vs9kzkkP9v03UTrzd9I8DuzjUcjCGe666rA20eBFL8ukIuZfXYwTTZAXLKhmtXxgnfyf6iU9EoLVqnqTHUp5pxgvGxEiTmFavbmEqo5hWqINjXU2vn6T0OXvt8pVsLNmQD1rEcPyWTnITgYfKoZmiH6fw75BbpJuu8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1821097852</pqid></control><display><type>article</type><title>Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Cross, Robert W. ; Mire, Chad E. ; Branco, Luis M. ; Geisbert, Joan B. ; Rowland, Megan M. ; Heinrich, Megan L. ; Goba, Augustine ; Momoh, Mambu ; Grant, Donald S. ; Fullah, Mohamed ; Khan, Sheik Humarr ; Robinson, James E. ; Geisbert, Thomas W. ; Garry, Robert F.</creator><creatorcontrib>Cross, Robert W. ; Mire, Chad E. ; Branco, Luis M. ; Geisbert, Joan B. ; Rowland, Megan M. ; Heinrich, Megan L. ; Goba, Augustine ; Momoh, Mambu ; Grant, Donald S. ; Fullah, Mohamed ; Khan, Sheik Humarr ; Robinson, James E. ; Geisbert, Thomas W. ; Garry, Robert F.</creatorcontrib><description>Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
•125 Lassa glycoprotein-specific huMAbs were assessed for in vitro activity.•Eleven huMAbs were assessed in an outbred guinea pig model of Lassa fever.•Five huMAbs completely protected animals when given shortly after Lassa exposure.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2016.08.012</identifier><identifier>PMID: 27531367</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacology ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - immunology ; Antibodies, Viral - pharmacology ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Guinea Pigs ; Humans ; Inhibitory Concentration 50 ; Lassa Fever - drug therapy ; Lassa Fever - immunology ; Lassa Fever - virology ; Lassa virus ; Lassa virus - drug effects ; Lassa virus - immunology ; Neutralization Tests</subject><ispartof>Antiviral research, 2016-09, Vol.133, p.218-222</ispartof><rights>2016 The Authors</rights><rights>Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-73e23871c6f5e14cf21f6c65e845b6aedc462979181ea5266a574daab6a354373</citedby><cites>FETCH-LOGICAL-c508t-73e23871c6f5e14cf21f6c65e845b6aedc462979181ea5266a574daab6a354373</cites><orcidid>0000-0002-5683-3250</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2016.08.012$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,315,782,786,887,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27531367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cross, Robert W.</creatorcontrib><creatorcontrib>Mire, Chad E.</creatorcontrib><creatorcontrib>Branco, Luis M.</creatorcontrib><creatorcontrib>Geisbert, Joan B.</creatorcontrib><creatorcontrib>Rowland, Megan M.</creatorcontrib><creatorcontrib>Heinrich, Megan L.</creatorcontrib><creatorcontrib>Goba, Augustine</creatorcontrib><creatorcontrib>Momoh, Mambu</creatorcontrib><creatorcontrib>Grant, Donald S.</creatorcontrib><creatorcontrib>Fullah, Mohamed</creatorcontrib><creatorcontrib>Khan, Sheik Humarr</creatorcontrib><creatorcontrib>Robinson, James E.</creatorcontrib><creatorcontrib>Geisbert, Thomas W.</creatorcontrib><creatorcontrib>Garry, Robert F.</creatorcontrib><title>Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
•125 Lassa glycoprotein-specific huMAbs were assessed for in vitro activity.•Eleven huMAbs were assessed in an outbred guinea pig model of Lassa fever.•Five huMAbs completely protected animals when given shortly after Lassa exposure.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibodies, Viral - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Guinea Pigs</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><subject>Lassa Fever - drug therapy</subject><subject>Lassa Fever - immunology</subject><subject>Lassa Fever - virology</subject><subject>Lassa virus</subject><subject>Lassa virus - drug effects</subject><subject>Lassa virus - immunology</subject><subject>Neutralization Tests</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcuOEzEQtBCIDQu_AD5ymcGP8WMuSKsV7CJF4rKcLcfTkziasYPtCeJv-Ba-DEdZIjjByS1XdXVXF0JvKGkpofLdvrWh-KNPdmpZ_WiJbgllT9CKasWanvTyKVpVQDZcdOwKvch5TwiRqtfP0RVTglMu1QrtHxLYMkMoOI54bXO2uMouGfswgis-hlrhuJRNggFvFx_A4oPfZvzNlx0efcql8aFxU-39-WO3zDbgOYbophjshE97buLgIb9Ez0Y7ZXj1-F6jLx8_PNzeN-vPd59ub9aNE0SXRnFgXCvq5CiAdm5kdJROCtCd2EgLg-sk61VPNQUrmJRWqG6wtmLVKlf8Gr0_6x6WzVzp1Vs9kzkkP9v03UTrzd9I8DuzjUcjCGe666rA20eBFL8ukIuZfXYwTTZAXLKhmtXxgnfyf6iU9EoLVqnqTHUp5pxgvGxEiTmFavbmEqo5hWqINjXU2vn6T0OXvt8pVsLNmQD1rEcPyWTnITgYfKoZmiH6fw75BbpJuu8</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Cross, Robert W.</creator><creator>Mire, Chad E.</creator><creator>Branco, Luis M.</creator><creator>Geisbert, Joan B.</creator><creator>Rowland, Megan M.</creator><creator>Heinrich, Megan L.</creator><creator>Goba, Augustine</creator><creator>Momoh, Mambu</creator><creator>Grant, Donald S.</creator><creator>Fullah, Mohamed</creator><creator>Khan, Sheik Humarr</creator><creator>Robinson, James E.</creator><creator>Geisbert, Thomas W.</creator><creator>Garry, Robert F.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5683-3250</orcidid></search><sort><creationdate>20160901</creationdate><title>Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies</title><author>Cross, Robert W. ; Mire, Chad E. ; Branco, Luis M. ; Geisbert, Joan B. ; Rowland, Megan M. ; Heinrich, Megan L. ; Goba, Augustine ; Momoh, Mambu ; Grant, Donald S. ; Fullah, Mohamed ; Khan, Sheik Humarr ; Robinson, James E. ; Geisbert, Thomas W. ; Garry, Robert F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-73e23871c6f5e14cf21f6c65e845b6aedc462979181ea5266a574daab6a354373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibodies, Viral - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Guinea Pigs</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><topic>Lassa Fever - drug therapy</topic><topic>Lassa Fever - immunology</topic><topic>Lassa Fever - virology</topic><topic>Lassa virus</topic><topic>Lassa virus - drug effects</topic><topic>Lassa virus - immunology</topic><topic>Neutralization Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cross, Robert W.</creatorcontrib><creatorcontrib>Mire, Chad E.</creatorcontrib><creatorcontrib>Branco, Luis M.</creatorcontrib><creatorcontrib>Geisbert, Joan B.</creatorcontrib><creatorcontrib>Rowland, Megan M.</creatorcontrib><creatorcontrib>Heinrich, Megan L.</creatorcontrib><creatorcontrib>Goba, Augustine</creatorcontrib><creatorcontrib>Momoh, Mambu</creatorcontrib><creatorcontrib>Grant, Donald S.</creatorcontrib><creatorcontrib>Fullah, Mohamed</creatorcontrib><creatorcontrib>Khan, Sheik Humarr</creatorcontrib><creatorcontrib>Robinson, James E.</creatorcontrib><creatorcontrib>Geisbert, Thomas W.</creatorcontrib><creatorcontrib>Garry, Robert F.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cross, Robert W.</au><au>Mire, Chad E.</au><au>Branco, Luis M.</au><au>Geisbert, Joan B.</au><au>Rowland, Megan M.</au><au>Heinrich, Megan L.</au><au>Goba, Augustine</au><au>Momoh, Mambu</au><au>Grant, Donald S.</au><au>Fullah, Mohamed</au><au>Khan, Sheik Humarr</au><au>Robinson, James E.</au><au>Geisbert, Thomas W.</au><au>Garry, Robert F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>133</volume><spage>218</spage><epage>222</epage><pages>218-222</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
•125 Lassa glycoprotein-specific huMAbs were assessed for in vitro activity.•Eleven huMAbs were assessed in an outbred guinea pig model of Lassa fever.•Five huMAbs completely protected animals when given shortly after Lassa exposure.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27531367</pmid><doi>10.1016/j.antiviral.2016.08.012</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-5683-3250</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0166-3542 |
| ispartof | Antiviral research, 2016-09, Vol.133, p.218-222 |
| issn | 0166-3542 1872-9096 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5032844 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Antibodies, Viral - pharmacology Disease Models, Animal Dose-Response Relationship, Drug Guinea Pigs Humans Inhibitory Concentration 50 Lassa Fever - drug therapy Lassa Fever - immunology Lassa Fever - virology Lassa virus Lassa virus - drug effects Lassa virus - immunology Neutralization Tests |
| title | Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T00%3A53%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Lassa%20virus%20infection%20in%20outbred%20guinea%20pigs%20with%20first-in-class%C2%A0human%20monoclonal%20antibodies&rft.jtitle=Antiviral%20research&rft.au=Cross,%20Robert%20W.&rft.date=2016-09-01&rft.volume=133&rft.spage=218&rft.epage=222&rft.pages=218-222&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2016.08.012&rft_dat=%3Cproquest_pubme%3E1821097852%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1821097852&rft_id=info:pmid/27531367&rft_els_id=S0166354216303515&rfr_iscdi=true |